US demand for diabetes monitoring products and therapies is expected to grow 9.5 percent annually through 2008. Gains will be driven by more diabetes patients and more aggressive treatments. Best prospects include electrochemical blood glucose test strips, prefilled disposable insulin pen injectors, and TZD and peptide agonist oral anti-diabetic agents.
This study analyzes the $11 billion US diabetes monitoring product and therapy industry. It presents historical (1993, 1998, 2003) demand data and forecasts to 2008 and 2013 by product (e.g., blood glucose tests and monitors, diabetes diagnostics, insulin injectors, insulin pumps and accessories, insulin dosages, oral anti-diabetic agents); and by market.
The study also considers market environment factors, details industry structure, evaluates company market share and profiles 24 major players including Eli Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson, Sanofi-Aventis, Roche, Bayer, Abbott Laboratories, Novo Nordisk, and Medtronic MiniMed.